<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Assess Targeted I/O Agents with PBMC-Humanized Models

There is an increasing need for fast, reliable, and cost-effective immunocompetent models for preclinical drug development. This includes targeted cancer immunotherapies, such as bispecific antibodies.